WT1 vaccine

BIOLOGICAL2 trials

Sponsors

Nakata Jun, Memorial Sloan Kettering Cancer Center

Conditions

Acute myeloid leukemia AMLFallopian TubeOvarian CancerPrimary Peritoneal CancerRecurrent Ovarian Cancer

Phase 1

A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer

CompletedNCT02737787

Memorial Sloan Kettering Cancer CenterFallopian Tube, Ovarian Cancer, Primary Peritoneal Cancer +1

Start: 2016-04-30End: 2023-04-06Updated: 2023-04-07

Phase 2

Investigator-initiated clinical trial (Phase II) of cancer vaccine "DSP-7888" for acute myeloid leukemia patients.

Active, not recruitingJPRN-jRCT2051200023

Nakata JunAcute myeloid leukemia AML

Start: 2020-06-12Target: 70Updated: 2026-06-29

Related Papers

A phase I study of concomitant galinpepimut-s (GPS) in combination with nivolumab (nivo) in patients (pts) with WT1+ ovarian cancer (OC) in second or third remission.

Journal of Clinical Oncology2018-05-206 citations